Gartner Research

Assessment of Track-and-Trace and Serialization Legislation for Life Science Companies, Africa

Published: 22 March 2016

ID: G00295584

Analyst(s): Andrew Stevens

Summary

Counterfeit pharmaceuticals are a serious problem in African countries, with formal legislation not anticipated in the near term. Supply chain leaders must take responsibility now for protecting patients.

Table Of Contents

Analysis

  • Introduction
  • Counterfeit Medicines in Africa Present a Serious and Immediate Challenge
  • Don't Wait for Legislation; Assess Immediate and Near-Term Risk Profiles for Products Sold in African Countries; Protect Patients as a Priority for Products at Highest Risk of Potential Counterfeiting
  • Assess the Market for Mobile Technology Authentication Solutions to Immediately Protect Patients Against Counterfeit Products; Be Sure to Scope Tamper-Evident Packaging and Seals as Part of the Broader Solution
    • Mobile Scanning and Bar Code Solutions
    • SMS Text Messaging With Special Tamper-Evident Labels
    • Chemical or Molecular Screening Technology
    • Further Developing Authentication Technologies
    • Tamper Evidence and Secure Packaging
  • Consider Early Collaboration Opportunities for Piloting New Authentication Technology Solutions and Supply Chain Practices for Protecting Against Counterfeit Pharmaceuticals
  • Introduce Prequalification and Quality-Testing Steps Close to Points of Dispensation or Patient Use

Gartner Recommended Reading

©2021 Gartner, Inc. and/or its affiliates. All rights reserved. Gartner is a registered trademark of Gartner, Inc. and its affiliates. This publication may not be reproduced or distributed in any form without Gartner’s prior written permission. It consists of the opinions of Gartner’s research organization, which should not be construed as statements of fact. While the information contained in this publication has been obtained from sources believed to be reliable, Gartner disclaims all warranties as to the accuracy, completeness or adequacy of such information. Although Gartner research may address legal and financial issues, Gartner does not provide legal or investment advice and its research should not be construed or used as such. Your access and use of this publication are governed by Gartner’s Usage Policy. Gartner prides itself on its reputation for independence and objectivity. Its research is produced independently by its research organization without input or influence from any third party. For further information, see Guiding Principles on Independence and Objectivity.

Already have a Gartner Account?

Become a client

Learn how to access this content as a Gartner client.